Keyphrases
Clinical Trials
100%
Rare Case Report
83%
Rapidly Progressive Glomerulonephritis
83%
Coronary Cameral Fistula
83%
IgA Vasculitis (IgAV)
83%
Brown Recluse Spider Bite
83%
Pertuzumab
83%
COVID-19 Recovery
83%
Oral Factor Xa Inhibitors
83%
Direct Oral
83%
Risk Outcomes
83%
Patient Outcomes
83%
Risk-benefit
83%
Osteopathy
83%
Fistula
83%
Corrected Covered Area
83%
Patient Benefit
83%
Drug Development
83%
COVID-19
83%
Osteopathic
83%
Left Heart Catheterization
83%
Harms Reporting
83%
Reporting Assessment
83%
Myocarditis
83%
Patient Risk
83%
High-dose Steroids
66%
Proteinuria
66%
Echocardiogram
59%
Spider Bite
55%
Palpable Purpura
50%
Breast Cancer
48%
Psychological Dysfunction
41%
Intensive Care Unit Stay
41%
Physical Dysfunction
41%
Disruptor
41%
Illness
41%
United States
41%
Potential Gains
41%
Acute Respiratory Distress Syndrome
41%
Wellness
41%
Post-infection
41%
Treatment Options
41%
Survivors
41%
Comprehensive Care
41%
Embase
34%
PubMed
34%
MEDLINE
34%
Inclusion Criteria
34%
Low Complement
33%
Leukocytoclastic Vasculitis
33%
Medicine and Dentistry
Clinical Trial
83%
COVID-19
83%
Pertuzumab
83%
Blood Clotting Factor 10a Inhibitor
83%
Coronary Artery Fistula
83%
Fistula
83%
Cross Sectional Study
83%
Systematic Review
83%
Cardiac Catheterization
83%
Osteopathic Medicine
55%
Echocardiography
52%
Breast Cancer
48%
Awareness
38%
Infection
27%
Physician
27%
Sequela
27%
Acute Respiratory Distress Syndrome
27%
Disease
27%
Intensive Care Unit
27%
Wellbeing
27%
Overall Survival
27%
Diastolic Dysfunction
20%
Combination Therapy
20%
Adverse Event
20%
Off-Label Use
20%
Sulfanilamide
20%
Myocardial Disease
20%
Congestive Heart Failure
20%
Mycophenolate Mofetil
16%
Weakness
10%
Case Presentation
10%
Artery
10%
Outpatient
10%
Dyspnea
10%
Coronary Artery
10%
Diagnosis
10%
Catheterization
10%
Drug Use
10%
Endocarditis
10%
Titrimetry
10%
Medical History
10%
Ischemia
10%
Cardiac Dysrhythmia
10%
Myocardial Infarction
10%
Tachyarrhythmia
10%
Patient Characteristics
10%
Aneurysm
10%
Thyrotropin
10%
Symptomatology
10%
Vital Sign
10%